Retatrutide Research & Studies
We track 21 published, PubMed-indexed studies for Retatrutide, spanning 2023 to 2026. The research below includes 13 reviews, 3 meta-analysiss, 5 clinical trials.
These summaries are for educational purposes. Research findings, particularly from preclinical studies, may not translate to human outcomes. Always consult a qualified healthcare provider before making decisions based on this information.
13
Reviews
3
Meta-Analysiss
5
Clinical Trials
Retatrutide in type 2 diabetes mellitus and obesity: an overview.
ReviewPanou T, Gouveri E, et al.|Expert Rev Clin Pharmacol|2026
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
Meta-AnalysisSinha B, Ghosal S|Obesity (Silver Spring)|2025
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
Meta-AnalysisTewari J, Qidwai KA, et al.|Expert Rev Clin Pharmacol|2025
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Clinical TrialCoskun T, Wu Q, et al.|Lancet Diabetes Endocrinol|2025
Retatrutide-A Game Changer in Obesity Pharmacotherapy.
ReviewKatsi V, Koutsopoulos G, et al.|Biomolecules|2025
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
ReviewAbdrabou Abouelmagd A, Abdelrehim AM, et al.|Proc (Bayl Univ Med Cent)|2025
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
ReviewMisra S, Narayan RK, Kaur M|J Basic Clin Physiol Pharmacol|2025
Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes.
ReviewOlowo-Oribi BA, Salway RJ|Acad Emerg Med|2025
What is the pipeline for future medications for obesity?
ReviewMelson E, Ashraf U, et al.|Int J Obes (Lond)|2025
Emerging pharmacotherapies for obesity: A systematic review.
ReviewKokkorakis M, Chakhtoura M, et al.|Pharmacol Rev|2025
Tirzepatide versus Semaglutide Once Weekly in Patients with Obesity or Overweight (SURMOUNT-5): a head-to-head comparison trial.
Clinical TrialRodriguez PJ, Goodwin B, et al.|N Engl J Med|2025
Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
Meta-AnalysisAyesh H, Ayesh S, Niswender K|Am J Ther|2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Clinical TrialSanyal AJ, Kaplan LM, et al.|Nat Med|2024
The power of three: Retatrutide's role in modern obesity and diabetes therapy.
ReviewAbdul-Rahman T, Roy P, et al.|Eur J Pharmacol|2024
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.
ReviewPasqualotto E, Ferreira ROM, et al.|Metabol Open|2024
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
ReviewKaur M, Misra S|Eur J Clin Pharmacol|2024
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
ReviewDrucker DJ|Diabetes Care|2024
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
ReviewLocatelli JC, Costa JG, et al.|Diabetes Care|2024
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Clinical TrialJastreboff AM, Kaplan LM, et al.|N Engl J Med|2023
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Clinical TrialRosenstock J, Frias J, et al.|Lancet|2023
Retatrutide showing promise in obesity (and type 2 diabetes).
ReviewDoggrell SA|Expert Opin Investig Drugs|2023